# Zimmer Biomet Holdings Moat

Status: published. Policy: company-analysis-1.

Zimmer Biomet has proprietary technology, established customer relationships and demonstrated product demand, but the passages do not establish durable differentiation or customer switching costs. Pricing power is weak: selling prices reduced first-half 2026 sales by 0.7%, including purchase incentives, following positive price realization in 2024. Procurement pressure and distribution disruption show erosion risks, while growth and cash generation argue against concluding that the franchise lacks competitive value. The evidence remains insufficient to establish a moat.

## intangible_assets

Proprietary technology and intellectual property are current business assets; their ability to confer durable competitive superiority remains unproven. Increased robot sales demonstrate demand, while expected benefits from acquired robotics remain potential.

Durability: No product-specific exclusivity periods, comparative clinical outcomes or sustained competitive gains establish the duration of an advantage. Accounting useful lives do not establish moat duration.

Risks: Technology substitution, patent circumvention and procurement pressure could weaken differentiation. Actual price declines demonstrate limited ability to monetize differentiation through higher prices.

Invalidation: The candidate advantage would be undermined by loss of material exclusivity accompanied by substitution, or sustained declines in differentiated-product demand despite continued development spending. Comparative product outcomes and sustained adoption attributable to protected technology would strengthen the case.

Competitors: Not established
## switching_costs

Product knowledge and professional customer relationships could support repeat business, but the passages do not demonstrate customer dependence, retraining costs or restrictions on switching suppliers.

Durability: Relationships exist, but their persistence and economic value are not quantified. They partly reside with employees and independent distributors rather than exclusively with the company.

Risks: Relationship portability, distributor changes and purchasing-group selection can interrupt access to customers. China distributor claims are realized disruption; possible future customer losses remain risks.

Invalidation: Documented customer migration following representative departures, or supplier changes without meaningful training or workflow disruption, would undermine the candidate switching-cost mechanism. Demonstrated repeat purchasing through competitive tenders and quantified workflow dependence would strengthen it.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/1136869/000119312526059853/zbh-20251231.htm](https://www.sec.gov/Archives/edgar/data/1136869/000119312526059853/zbh-20251231.htm) · 2026-02-20
- [https://www.sec.gov/Archives/edgar/data/1136869/000119312526335044/zbh-20260630.htm](https://www.sec.gov/Archives/edgar/data/1136869/000119312526335044/zbh-20260630.htm) · 2026-08-05
- [https://www.sec.gov/Archives/edgar/data/1136869/000119312526135661/zbh-20260331.htm](https://www.sec.gov/Archives/edgar/data/1136869/000119312526135661/zbh-20260331.htm) · 2026-04-01
- [https://www.sec.gov/Archives/edgar/data/1136869/000095017025026604/zbh-20241231.htm](https://www.sec.gov/Archives/edgar/data/1136869/000095017025026604/zbh-20241231.htm) · 2025-02-25
- [https://www.sec.gov/Archives/edgar/data/1136869/000095017024019353/zbh-20231231.htm](https://www.sec.gov/Archives/edgar/data/1136869/000095017024019353/zbh-20231231.htm) · 2024-02-23
- [https://www.sec.gov/Archives/edgar/data/1136869/000119312526201710/zbh-20260331.htm](https://www.sec.gov/Archives/edgar/data/1136869/000119312526201710/zbh-20260331.htm) · 2026-05-01

[JSON](https://beanvest.com/stock/zbh/moat.json)